Alnylam Pharmaceuticals Inc (ALNY)vsNovavax Inc (NVAX)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
NVAX
Novavax Inc
$9.34
+0.86%
HEALTHCARE · Cap: $1.57B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 231% more annual revenue ($3.71B vs $1.12B). NVAX leads profitability with a 39.2% profit margin vs 8.5%. NVAX trades at a lower P/E of 3.7x. NVAX earns a higher WallStSmart Score of 56/100 (C).
ALNY
Hold49
out of 100
Grade: D+
NVAX
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
+48.9%
Fair Value
$17.54
Current Price
$9.34
$8.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Attractively priced relative to earnings
Keeps 39 of every $100 in revenue as profit
Revenue surging 66.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Smaller company, higher risk/reward
ROE of -9.0% — below average capital efficiency
Earnings declined 38.1%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : NVAX
The strongest argument for NVAX centers on P/E Ratio, Profit Margin, Revenue Growth. Profitability is solid with margins at 39.2% and operating margin at 14.2%. Revenue growth of 66.6% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : NVAX
The primary concerns for NVAX are Market Cap, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while NVAX is a growth play — different risk/reward profiles.
NVAX carries more volatility with a beta of 2.63 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
NVAX scores higher overall (56/100 vs 49/100), backed by strong 39.2% margins and 66.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Novavax Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?